Harry Burn’s Teva Pharmaceuticals TEVA Stock Holding History

Harry Burn’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$129M	Sell	3,804,497 -81,186	-2%	-$2.7M	3.97%	1
2026 Q1	$117M	Sell	3,885,683 -424,223	-10%	-$13.6M	3.92%	1
2025 Q4	$135M	Sell	4,309,906 -1,337,543	-24%	-$33M	4.28%	2
2025 Q3	$114M	Sell	5,647,449 -199,063	-3%	-$3.5M	3.77%	1
2025 Q2	$98M	Buy	5,846,512 +394,423	+7%	+$6.36M	3.34%	7
2025 Q1	$83.8M	Buy	5,452,089 +679,377	+14%	+$12.1M	2.94%	16
2024 Q4	$105M	Sell	4,772,712 -1,204,132	-20%	-$21.9M	3.47%	3
2024 Q3	$108M	Sell	5,976,844 -784,602	-12%	-$13.7M	3.5%	2
2024 Q2	$110M	Sell	6,761,446 -733,244	-10%	-$11.3M	3.66%	1
2024 Q1	$106M	Sell	7,494,690 -1,424,544	-16%	-$18M	3.31%	7
2023 Q4	$93.1M	Buy	8,919,234 +998,522	+13%	+$9.32M	3.23%	8
2023 Q3	$80.8M	Buy	+7,920,712	New	+$73.8M	3.09%	9

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Harry Burn's TEVA Position: Q2 2026 in Review

Harry Burn reduced its Teva Pharmaceuticals (TEVA) stake by 2.1% in Q2 2026, selling an estimated $2.7M and leaving 3,804,497 shares worth $129M. The position accounts for 3.97% of the portfolio, ranked #1.

Harry Burn first reported a position in TEVA in Q3 2023 and has held it in 12 quarters since. The position peaked at $135M in Q4 2025. 671 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Harry Burn held 3,804,497 shares of Teva Pharmaceuticals worth $129M as of Q2 2026.
Harry Burn sold 81,186 Teva Pharmaceuticals shares in Q2 2026, an estimated $2.7M.
Teva Pharmaceuticals made up 3.97% of Harry Burn's portfolio in Q2 2026, its #1 holding.
Harry Burn first reported a position in Teva Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
Harry Burn's Teva Pharmaceuticals position peaked at $135M in Q4 2025.
671 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Sound Shore Management's 13F filing for Q2 2026, filed 12 Aug 2026.